Health and Healthcare
Mannkind Sinks on Afrezza License Termination
Published:
Last Updated:
MannKind Corp. (NASDAQ: MNKD) is one of the most traded biotech companies on the market, and one of the most shorted as well. In Tuesday’s session the stock took a big downturn after the company decided to terminate its insulin inhaler project with Sanofi-Aventis.
MannKind announced the termination of its license and collaboration agreement with Sanofi U.S. for the development and commercialization of Afrezza (insulin human) Inhalation Powder. Both parties promptly will commence transition discussions in order to effect a smooth and orderly transition in the development and commercialization of Afrezza from Sanofi to MannKind over the next 90 to 180 days.
In any event, termination of the license agreement in its entirety will be effective no later than six months from the effective date of Sanofi’s notice of termination, or July 4, 2016.
Over the course of the past 52 weeks MannKind, has vastly underperformed the market, with the stock down nearly 75%.
As of the most recent short interest settlement date, MannKind’s short interest totaled 111.52 million shares with 19 days to cover.
Tuesday morning, shares of MannKind fell to a new 52-week low of $0.96. The consensus analyst price target is $4.80, and the 52-week high is $7.88.
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.